Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.

IF 1.2 Q4 ONCOLOGY Hepatic Oncology Pub Date : 2021-07-13 eCollection Date: 2022-03-01 DOI:10.2217/hep-2020-0031

Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni

{"title":"Transarterial chemoembolization alone or followed by bevacizumab for treatment of colorectal liver metastases.","authors":"Giammaria Fiorentini, Donatella Sarti, Michele Nardella, Riccardo Inchingolo, Massimiliano Nestola, Alberto Rebonato, Caterina Fiorentini, Camillo Aliberti, Roberto Nani, Stefano Guadagni","doi":"10.2217/hep-2020-0031","DOIUrl":null,"url":null,"abstract":"Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status.Patients & methods: This was an observational multicentric case-control study (NCT03732235) on the efficacy and safety of B administered after TACE.Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01).Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2021-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ce/dd/hep-09-40.PMC8577510.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Aims: Bevacizumab (B) in association with systemic chemotherapy is commonly used for the treatment of colorectal cancer liver metastases. The aim of this study was to monitor tumor response, overall survival (OS) and progression-free survival (PFS) of patients with colorectal cancer liver metastases treated with transarterial chemoembolization (TACE) + B compared with TACE alone and to correlate the results with KRAS mutational status.

Patients & methods: This was an observational multicentric case-control study (NCT03732235) on the efficacy and safety of B administered after TACE.

Results: The disease control rate was significantly higher for the TACE + B than the TACE alone group (p < 0.001). KRAS wild-type patients had a significantly better disease control rate than those with KRAS mutations in the TACE + B group. Median OS and PFS were similar for the TACE + B and TACE groups, whereas median time to progression was significantly higher for the TACE + B group (p < 0.01).

Conclusion: The combination of TACE with B may improve tumor response and delay disease progression.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

经动脉化疗栓塞单独或随后贝伐单抗治疗结肠直肠癌肝转移。

目的：贝伐单抗（B）联合全身化疗是治疗结直肠癌癌症肝转移的常用药物。本研究的目的是监测经动脉化疗栓塞（TACE）+B与单纯TACE治疗的结直肠癌癌症肝转移患者的肿瘤反应、总生存率（OS）和无进展生存率（PFS），并将结果与KRAS突变状态相关联。患者和方法：这是一项关于TACE后使用B的疗效和安全性的观察性多中心病例对照研究（NCT03732235）。结果：TACE+B组的疾病控制率明显高于单纯TACE组（p KRAS野生型患者的疾病控制效率明显高于TACE+B组中有KRAS突变的患者（p结论：TACE与B联合应用可改善肿瘤反应，延缓疾病进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.